PDF(Pubmed)
Abstract：
Breast augmentation is considered safe, but rare cases of breast implant-associated squamous cell carcinoma (BIA-SCC) have been reported. This study aimed to systematically review published cases of BIA-SCC, providing valuable clinical data. The review included 14 articles and 18 cases of BIA-SCC. An increasing trend in reported BIA-SCC cases was observed, with four cases in the 1990s and 14 cases since 2010. The mean age of affected patients was 56 years, and symptoms typically appeared around 21 years after breast augmentation. Silicone implants used in cosmetic procedures were most commonly associated with BIA-SCC. Implant removal was necessary in all cases, and some patients required a mastectomy. Treatment approaches varied, with the selective use of chemotherapy and/or radiotherapy. The estimated 6-month mortality rate was 11.1%, while the 12-month mortality rate was 23.8%. The estimated 6-month mortality rate should be cautiously interpreted due to the limited sample size. It appears lower than the rate reported by the American Society of Plastic Surgeons, without clear reasons for this discrepancy. This study highlights the importance of enhanced monitoring and information sharing to improve detection and management of BIA-SCC. Healthcare providers should maintain vigilance during the long-term follow-up of breast augmentation patients.
摘要：
隆胸被认为是安全的,但乳腺植入物相关鳞状细胞癌(BIA-SCC)的罕见病例已有报道.本研究旨在系统回顾已发表的BIA-SCC病例，提供有价值的临床数据。审查包括14篇文章和18例BIA-SCC。观察到报告的BIA-SCC病例呈上升趋势，上世纪90年代有4例，2010年以来有14例。受影响患者的平均年龄为56岁，症状通常在隆胸后21年左右出现。用于整容手术的有机硅植入物最常与BIA-SCC相关。在所有情况下都需要去除植入物，有些病人需要做乳房切除手术.治疗方法多种多样，选择性使用化疗和/或放疗。估计6个月死亡率为11.1%,而12个月死亡率为23.8%。由于样本量有限，估计的6个月死亡率应谨慎解释。它似乎低于美国整形外科学会报告的比率，没有明确的原因，这种差异。这项研究强调了加强监测和信息共享对改善BIA-SCC检测和管理的重要性。医疗保健提供者在隆胸患者的长期随访期间应保持警惕。
